America’s Obesity Crisis: Is Ozempic a Cure or a Cover-Up? | Calley Means and Tyna Moore

This podcast episode discusses the complexities of weight loss, contrasting the traditional "calories in, calories out" model with the carbohydrate-insulin model. Dr. Hyman interviews a colleague who advocates for microdosing GLP-1 agonists to address metabolic dysfunction and inflammation, rather than solely focusing on weight loss. The discussion highlights the potential benefits and risks of GLP-1 agonists, emphasizing the importance of considering individual metabolic needs and avoiding high doses. A key takeaway is that the quality of calories, not just quantity, significantly impacts weight and overall health, with ultra-processed foods being a major contributor to metabolic issues. The episode concludes by suggesting a more holistic approach to weight management that addresses root causes and individual needs.